SARS-CoV-2 vaccine development, access, and equity
Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of...
Gespeichert in:
| Veröffentlicht in: | The Journal of experimental medicine 2020-11, Vol.217 (11) |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | |
| container_title | The Journal of experimental medicine |
| container_volume | 217 |
| creator | Kim, Jerome H |
| description | Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective. |
| doi_str_mv | 10.1084/jem.20201288 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7563686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451858854</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-4529f78aafa7ceadab842e7bd123557935e699898a9054e2b912274edce32a2d3</originalsourceid><addsrcrecordid>eNpVkE1Lw0AQhhdRbK3ePEuOHpq6O7ub7F6EUvwCQbDqddlsJpqSjzabFPrvTekHehp45-Gd4SHkmtEJo0rcLbCcAAXKQKkTMmRS0FBLrk7JkFKAkFEaD8iF9wtKmRAyOicDzmkkmGRDAvPp-zyc1V8hBGvrXF5hkOIai3pZYtWOgz5D7_tZpQGuurzdXJKzzBYer_ZzRD4fHz5mz-Hr29PLbPoaOq5EGwoJOouVtZmNHdrUJkoAxknKgEsZay4x0lppZTWVAiHRDCAWmDrkYCHlI3K_6112SbmNq7axhVk2eWmbjaltbv5vqvzHfNdrE8uIRyrqC273BU296tC3psy9w6KwFdadNyAkU1IpKXp0vENdU3vfYHY8w6jZaja9ZnPQ3OM3f187wgev_BdycXdm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451858854</pqid></control><display><type>article</type><title>SARS-CoV-2 vaccine development, access, and equity</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kim, Jerome H</creator><creatorcontrib>Kim, Jerome H</creatorcontrib><description>Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective.</description><identifier>ISSN: 0022-1007</identifier><identifier>EISSN: 1540-9538</identifier><identifier>DOI: 10.1084/jem.20201288</identifier><identifier>PMID: 33064151</identifier><language>eng</language><publisher>United States: Rockefeller University Press</publisher><subject>Animals ; Antibodies, Viral - immunology ; Betacoronavirus - immunology ; Biomedical Research - methods ; Coronavirus Infections - immunology ; Coronavirus Infections - prevention & control ; Coronavirus Infections - virology ; COVID-19 ; COVID-19 Vaccines ; Host Microbial Interactions - immunology ; Humans ; Immunogenicity, Vaccine ; Infectious Disease and Host Defense ; Pandemics - prevention & control ; Pneumonia, Viral - immunology ; Pneumonia, Viral - prevention & control ; Pneumonia, Viral - virology ; SARS-CoV-2 ; Vaccination ; Viewpoint ; Viral Vaccines - immunology</subject><ispartof>The Journal of experimental medicine, 2020-11, Vol.217 (11)</ispartof><rights>2020 Kim.</rights><rights>2020 Kim 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-4529f78aafa7ceadab842e7bd123557935e699898a9054e2b912274edce32a2d3</citedby><cites>FETCH-LOGICAL-c384t-4529f78aafa7ceadab842e7bd123557935e699898a9054e2b912274edce32a2d3</cites><orcidid>0000-0003-0461-6438</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33064151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Jerome H</creatorcontrib><title>SARS-CoV-2 vaccine development, access, and equity</title><title>The Journal of experimental medicine</title><addtitle>J Exp Med</addtitle><description>Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective.</description><subject>Animals</subject><subject>Antibodies, Viral - immunology</subject><subject>Betacoronavirus - immunology</subject><subject>Biomedical Research - methods</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - prevention & control</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Host Microbial Interactions - immunology</subject><subject>Humans</subject><subject>Immunogenicity, Vaccine</subject><subject>Infectious Disease and Host Defense</subject><subject>Pandemics - prevention & control</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - prevention & control</subject><subject>Pneumonia, Viral - virology</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>Viewpoint</subject><subject>Viral Vaccines - immunology</subject><issn>0022-1007</issn><issn>1540-9538</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1Lw0AQhhdRbK3ePEuOHpq6O7ub7F6EUvwCQbDqddlsJpqSjzabFPrvTekHehp45-Gd4SHkmtEJo0rcLbCcAAXKQKkTMmRS0FBLrk7JkFKAkFEaD8iF9wtKmRAyOicDzmkkmGRDAvPp-zyc1V8hBGvrXF5hkOIai3pZYtWOgz5D7_tZpQGuurzdXJKzzBYer_ZzRD4fHz5mz-Hr29PLbPoaOq5EGwoJOouVtZmNHdrUJkoAxknKgEsZay4x0lppZTWVAiHRDCAWmDrkYCHlI3K_6112SbmNq7axhVk2eWmbjaltbv5vqvzHfNdrE8uIRyrqC273BU296tC3psy9w6KwFdadNyAkU1IpKXp0vENdU3vfYHY8w6jZaja9ZnPQ3OM3f187wgev_BdycXdm</recordid><startdate>20201102</startdate><enddate>20201102</enddate><creator>Kim, Jerome H</creator><general>Rockefeller University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0461-6438</orcidid></search><sort><creationdate>20201102</creationdate><title>SARS-CoV-2 vaccine development, access, and equity</title><author>Kim, Jerome H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-4529f78aafa7ceadab842e7bd123557935e699898a9054e2b912274edce32a2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antibodies, Viral - immunology</topic><topic>Betacoronavirus - immunology</topic><topic>Biomedical Research - methods</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - prevention & control</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Host Microbial Interactions - immunology</topic><topic>Humans</topic><topic>Immunogenicity, Vaccine</topic><topic>Infectious Disease and Host Defense</topic><topic>Pandemics - prevention & control</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - prevention & control</topic><topic>Pneumonia, Viral - virology</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>Viewpoint</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Jerome H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Jerome H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SARS-CoV-2 vaccine development, access, and equity</atitle><jtitle>The Journal of experimental medicine</jtitle><addtitle>J Exp Med</addtitle><date>2020-11-02</date><risdate>2020</risdate><volume>217</volume><issue>11</issue><issn>0022-1007</issn><eissn>1540-9538</eissn><abstract>Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective.</abstract><cop>United States</cop><pub>Rockefeller University Press</pub><pmid>33064151</pmid><doi>10.1084/jem.20201288</doi><orcidid>https://orcid.org/0000-0003-0461-6438</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1007 |
| ispartof | The Journal of experimental medicine, 2020-11, Vol.217 (11) |
| issn | 0022-1007 1540-9538 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7563686 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Antibodies, Viral - immunology Betacoronavirus - immunology Biomedical Research - methods Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronavirus Infections - virology COVID-19 COVID-19 Vaccines Host Microbial Interactions - immunology Humans Immunogenicity, Vaccine Infectious Disease and Host Defense Pandemics - prevention & control Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Pneumonia, Viral - virology SARS-CoV-2 Vaccination Viewpoint Viral Vaccines - immunology |
| title | SARS-CoV-2 vaccine development, access, and equity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A44%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SARS-CoV-2%20vaccine%20development,%20access,%20and%20equity&rft.jtitle=The%20Journal%20of%20experimental%20medicine&rft.au=Kim,%20Jerome%20H&rft.date=2020-11-02&rft.volume=217&rft.issue=11&rft.issn=0022-1007&rft.eissn=1540-9538&rft_id=info:doi/10.1084/jem.20201288&rft_dat=%3Cproquest_pubme%3E2451858854%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451858854&rft_id=info:pmid/33064151&rfr_iscdi=true |